Imaging hypoxia in orthotopic rat liver tumors with iodine 124-labeled iodoazomycin galactopyranoside PET

Radiology

Volumn 248, Issue 2, 2008, Pages 561-570

  Riedl, Christopher C ^a   Brader, Peter ^a   Zanzonico, Pat B ^a   Yun, Shin Chun ^a   Woo, Yanghee ^a   Singh, Paramjeet ^a   Carlin, Sean ^a   Wen, Bixiu ^a   Ling, C Clifton ^a   Hricak, Hedvig ^a   Fong, Yuman ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 NITRO 1H IMIDAZOL 1 YL) N (2,2,3,3,3 PENTAFLUOROPROPYL)ACETAMIDE; BIOLOGICAL MARKER; HOE 33342; IODINE 124; IODOAZOMYCIN GALACTOPYRANOSIDE I 124; NITROIMIDAZOLE DERIVATIVE; OXYGEN; PIMONIDAZOLE; UNCLASSIFIED DRUG; IODINATED AZOMYCIN GALACTOPYRANOSIDE; MONOSACCHARIDE; RADIOACTIVE IODINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; CORRELATION ANALYSIS; DRUG UPTAKE; HYPOXIA; IMMUNOFLUORESCENCE; ISOTOPE LABELING; MORRIS HEPATOMA; NONHUMAN; NUDE RAT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RAT; TIME; TISSUE OXYGENATION; TISSUE SECTION; ANIMAL; ANOXIA; IMAGE PROCESSING; LIVER CELL CARCINOMA; LIVER TUMOR; METABOLISM; MORTALITY; SCINTISCANNING;

ANIMALS; ANOXIA; CARCINOMA, HEPATOCELLULAR; IMAGE PROCESSING, COMPUTER-ASSISTED; IODINE RADIOISOTOPES; LIVER NEOPLASMS; MONOSACCHARIDES; NITROIMIDAZOLES; POSITRON-EMISSION TOMOGRAPHY; RATS; RATS, NUDE;

EID: 49049092403     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.2482071421     Document Type: Article

References (31)

1. Fyles A, Milosevic M, Hedley D, et al. Tumor hypoxia has independent predictor impact only in patients with node-negative cervix cancer. J Clin Oncol 2002;20:680-687.
2. Koukourakis MI, Giatromanolaki A, Sivridis E, et al. Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer. Int J Radiat Oncol Biol Phys 2002;53:1192-1202.
3. Loncaster JA, Harris AL, Davidson SE, et al. Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res 2001;61:6394-6399.
4. Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev 2007;26:225-239.
5. Zhong H, De Marzo AM, Laughner E, et al. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 1999;59:5830-5835.
6. van Laarhoven HW, Kaanders JH, Lok J, et al. Hypoxia in relation to vasculature and proliferation in liver metastases in patients with colorectal cancer. Int J Radiat Oncol Biol Phys 2006;64:473-482.
7. Rischin D, Hicks RJ, Fisher R, et al. Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02. J Clin Oncol 2006;24:2098-2104.
8. Landuyt W, Hermans R, Bosmans H, et al. BOLD contrast fMRI of whole rodent tumour during air or carbogen breathing using echoplanar imaging at 1.5 T. Eur Radiol 2001;11:2332-2340.
9. Barthel H, Wilson H, Collingridge DR, et al. In vivo evaluation of [18F]fluoroetanidazole as a new marker for imaging tumour hypoxia with positron emission tomography. Br J Cancer 2004;90:2232-2242.
10. Bruehlmeier M, Roelcke U, Schubiger PA, Ametamey SM. Assessment of hypoxia and perfusion in human brain tumors using PET with 18F- fluoromisonidazole and 15O-H2O. J Nucl Med 2004;45:1851-1859.
11. Brurberg KG, Graff BA, Rofstad EK. Temporal heterogeneity in oxygen tension in human melanoma xenografts. Br J Cancer 2003;89:350-356.
12. Chapman JD, Engelhardt EL, Stobbe CC, Schneider RF, Hanks GE. Measuring hypoxia and predicting tumor radioresistance with nuclear medicine assays. Radiother Oncol 1998;46:229-237.
13. Dehdashti F, Grigsby PW, Mintun MA, Lewis JS, Siegel BA, Welch MJ. Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: relationship to therapeutic response - a preliminary report. Int J Radiat Oncol Biol Phys 2003;55:1233-1238.
14. Rajendran JG, Schwartz DL, O'Sullivan J, et al. Tumor hypoxia imaging with [F-18] fluoromisonidazole positron emission tomography in head and neck cancer. Clin Cancer Res 2006;12:5435-5441.
15. Rasey JS, Koh WJ, Evans ML, et al. Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: a pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys 1996;36:417-428.
16. Valk PE, Mathis CA, Prados MD, Gilbert JC, Budinger TF. Hypoxia in human gliomas: demonstration by PET with fluorine-18-fluoromisonidazole. J Nucl Med 1992;33:2133-2137.
17. Yuan H, Schroeder T, Bowsher JE, Hedlund LW, Wong T, Dewhirst MW. Intertumoral differences in hypoxia selectivity of the PET imaging agent 64Cu(II)-diacetylbis(N4-methylthiosemicarbazone). J Nucl Med 2006;47:989 -998.
18. O'Donoghue JA, Zanzonico P, Pugachev A, et al. Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N4- methylthiosemicarbazone) positron emission tomography: comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models. Int J Radiat Oncol Biol Phys 2005;61:1493-1502.
19. Sambrook J, Gething MJ. Protein structure: chaperones, paperones. Nature 1989;342:224-225.
20. Serganova I, Humm J, Ling C, Blasberg R. Tumor hypoxia imaging. Clin Cancer Res 2006;12:5260-5264.
21. Zanzonico P, O'Donoghue J, Chapman JD, et al. Iodine-124-labeled iodo-azomycin-galactoside imaging of tumor hypoxia in mice with serial microPET scanning. Eur J Nucl Med Mol Imaging 2004;31:117-128.
22. Ziemer LS, Evans SM, Kachur AV, et al. Noninvasive imaging of tumor hypoxia in rats using the 2-nitroimidazole 18F-EF5. Eur J Nucl Med Mol Imaging 2003;30:259-266.
23. Griffiths JR, Robinson SP. The OxyLite: a fibre-optic oxygen sensor. Br J Radiol 1999;72:627-630.
24. Raleigh JA, Calkins-Adams DP, Rinker LH, et al. Hypoxia and vascular endothelial growth factor expression in human squamous cell carcinomas using pimonidazole as a hypoxia marker. Cancer Res 1998;58:3765-3768.
25. Evans SM, Hahn S, Pook DR, et al. Detection of hypoxia in human squamous cell carcinoma by EF5 binding. Cancer Res 2000;60:2018-2024.
26. Laughlin KM, Evans SM, Jenkins WT, et al. Biodistribution of the nitroimidazole EF5 [2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl) acetamide] in mice bearing subcutaneous EMT6 tumors. J Pharmacol Exp Ther 1996;277:1049-1057.
27. Riedl CC, Brader P, Zanzonico P, et al. Tumor hypoxia imaging in orthotopic liver tumors and peritoneal metastasis: a comparative study featuring dynamic (18)F-MISO and (124)I-IAZG PET in the same study cohort. Eur J Nucl Med Mol Imaging 2008;35:39-46.
28. Schroeder T, Yuan H, Viglianti BL, et al. Spatial heterogeneity and oxygen dependence of glucose consumption in R3230Ac and fibrosarcomas of the Fischer 344 rat. Cancer Res 2005;65:5163-5171.
29. Evans SM, Hahn SM, Magarelli DP, Koch CJ. Hypoxic heterogeneity in human tumors: EF5 binding, vasculature, necrosis, and proliferation. Am J Clin Oncol 2001;24:467-472.
30. Kaanders JH, Wijffels KI, Marres HA, et al. Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer. Cancer Res 2002;62:7066-7074.
31. Magagnin MG, Koritzinsky M, Wouters BG. Patterns of tumor oxygenation and their influence on the cellular hypoxic response and hypoxia-directed therapies. Drug Resist Updat 2006;9:185-197.